Confo Therapeutics is an emerging drug discovery company built around a disruptive technology to enable the discovery of GPCR agonists. The CONFO® technology uses single domain antibodies to lock inherently unstable GPCRs in the druggable conformation and uses this stabilized complex as a superior starting point for GPCR drug discovery. 



Biotechnology

Confo Therapeutics

Cedric Ververken

Geert Degruyter

Bruno Ranschaert

Thomas Fontaine

Richa Virmani

Caroline Segers

Andreas Busch

Stephen Dowd

Christel Menet

Frank Landolt

Paolo Vicini

Stephanie Staelens

Marc Moens

The Research and Development team at Confo Therapeutics focuses on utilizing the CONFO® technology to discover and develop novel GPCR agonists. This multidisciplinary team, comprised of experts in drug discovery, medical affairs, and strategic development, collaboratively works to advance early-stage projects from concept to clinical application, ensuring innovative therapeutic solutions are brought to market effectively.

Research and Development

Leadership Team

Research and Development

About

Team members

Other teams at Confo Therapeutics

Leadership Team

Research and Development